| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Josef Penninger | Q1674391 |
| Verena Sigl | Q96091465 | ||
| Laundette P Jones | Q125251393 | ||
| P2860 | cites work | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| Central control of fever and female body temperature by RANKL/RANK | Q24321735 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor | Q24555775 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer | Q24605866 | ||
| Mammary stem cells and the differentiation hierarchy: current status and perspectives | Q27003345 | ||
| Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial | Q27860743 | ||
| The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development | Q28142247 | ||
| RANK-L and RANK: T cells, bone loss, and mammalian evolution | Q28203468 | ||
| Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 | Q28212276 | ||
| Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab | Q28265584 | ||
| RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis | Q28294501 | ||
| IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development | Q28508430 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Triple-Negative Breast Cancer | Q29391607 | ||
| Generation of a functional mammary gland from a single stem cell | Q29616496 | ||
| Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies | Q29617680 | ||
| Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 | ||
| Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data | Q33239350 | ||
| The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells | Q33652431 | ||
| Osteoclasts: more than 'bone eaters'. | Q33993757 | ||
| The mechanisms of estrogen regulation of bone resorption | Q34086515 | ||
| International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers | Q34116505 | ||
| Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation | Q34129784 | ||
| The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts | Q34183259 | ||
| Breast cancer and hormone-replacement therapy in the Million Women Study | Q34223870 | ||
| Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. | Q34319242 | ||
| Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. | Q34334383 | ||
| Signaling pathways in mammary gland development. | Q34434909 | ||
| Receptor activator of NF-kappaB (RANK) stimulates the proliferation of epithelial cells of the epidermo-pilosebaceous unit | Q34750367 | ||
| Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling | Q35194008 | ||
| From milk to malignancy: the role of mammary stem cells in development, pregnancy and breast cancer | Q35348210 | ||
| The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. | Q53370119 | ||
| LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. | Q54200830 | ||
| A role for Brca1 in chromosome end maintenance | Q57790639 | ||
| Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton | Q57904787 | ||
| Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2 | Q59238517 | ||
| BRCA1 Inhibition of Estrogen Receptor Signaling in Transfected Cells | Q60568779 | ||
| Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis | Q83392350 | ||
| Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study | Q84453968 | ||
| Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria | Q86959921 | ||
| Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer | Q35957703 | ||
| IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells | Q36023768 | ||
| Repression of mammary stem/progenitor cells by p53 is mediated by Notch and separable from apoptotic activity | Q36113210 | ||
| RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1. | Q36200979 | ||
| Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers | Q36252676 | ||
| Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies | Q36368636 | ||
| BRCA1 regulates human mammary stem/progenitor cell fate | Q36446479 | ||
| The role of BRCA1 in transcriptional regulation and cell cycle control | Q36602565 | ||
| Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects | Q36602578 | ||
| BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer | Q36732507 | ||
| BRCA1, hormone, and tissue-specific tumor suppression | Q37020551 | ||
| BRCA1 and BRCA2: different roles in a common pathway of genome protection | Q37149848 | ||
| Genetic predisposition to breast cancer: past, present, and future | Q37187786 | ||
| Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment | Q37309421 | ||
| RANKL/RANK control Brca1 mutation-driven mammary tumors | Q37457304 | ||
| Osteoimmunology: crosstalk between the immune and bone systems | Q37544448 | ||
| Lgr4 regulates mammary gland development and stem cell activity through the pluripotency transcription factor Sox2. | Q37602035 | ||
| Clinical practice. Breast-cancer screening | Q37931934 | ||
| How pregnancy at early age protects against breast cancer | Q38172737 | ||
| The mammary stem cell hierarchy. | Q38179662 | ||
| The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer | Q38721385 | ||
| Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage. | Q38764888 | ||
| RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. | Q39670403 | ||
| Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist | Q40202330 | ||
| Soluble RANKL and risk of nontraumatic fracture | Q40527958 | ||
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial | Q40872467 | ||
| RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla | Q41868543 | ||
| Progesterone induces adult mammary stem cell expansion | Q42471079 | ||
| Control of mammary stem cell function by steroid hormone signalling. | Q43103606 | ||
| Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations | Q43520691 | ||
| Pharmacological properties of mifepristone: toxicology and safety in animal and human studies | Q44707949 | ||
| The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. | Q45802281 | ||
| "The race" to clone BRCA1. | Q48081790 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoporosis | Q165328 |
| breast neoplasm | Q23929670 | ||
| TNF superfamily member 11 | Q418934 | ||
| TNF receptor superfamily member 11a | Q906651 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P577 | publication date | 2016-11-01 | |
| P1433 | published in | Open Biology | Q7095958 |
| P1476 | title | RANKL/RANK: from bone loss to the prevention of breast cancer | |
| P478 | volume | 6 |
| Q50033721 | Breast cancer in young women: do BRCA1 or BRCA2 mutations matter? |
| Q38682103 | Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort |
| Q92636699 | Clinical Impact of RANK Signalling in Ovarian Cancer |
| Q64939796 | RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review. |
| Q90547034 | RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women |
| Q64903679 | RANKL/RANK Pathway and Its Inhibitor RANK-Fc in Uterine Leiomyoma Growth. |
| Q60917149 | RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives |
| Q89186597 | Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level |
| Q97643643 | Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone |
| Q57790452 | The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases |
| Q64102143 | The RANKL-RANK Axis: A Bone to Thymus Round Trip |
| Q91662693 | Therapeutic potentials and modulatory mechanisms of fatty acids in bone |
| Q59335358 | Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer |
Search more.